摘要 |
<p>Disclosed is a morpholine derivative represented by the formula [I] below, which is useful as a renin inhibitor, or a pharmacologically acceptable salt thereof. (In the formula, R1 represents (A) an alkyl group substituted with a group selected from optionally substituted alkoxy groups or the like, (B) an optionally substituted aryl group, (C) an optionally substituted heterocyclic group, (D) a cycloalkyl group or (E) an alkyl group; R2 represents (A) an alkyl group substituted with a group selected from optionally substituted alkoxy groups or the like, (B) an optionally substituted aryl group, (C) an optionally substituted heterocyclic group, (D) an optionally substituted alkylcarbonyl group, (E) an optionally substituted arylcarbonyl group, (F) an optionally substituted heterocyclic group-substituted carbonyl group or (G) a cycloalkylcarbonyl group; T represents a methylene group or a carbonyl group; and R3, R4, R5 and R6 may be the same or different, and each represents a hydrogen atom, an optionally substituted carbamoyl group or an optionally substituted alkyl group.)</p> |
申请人 |
MITSUBISHI TANABE PHARMA CORPORATION;SHANGAI PHARMACEUTICAL (GROUP) CO., LTD. |
发明人 |
AKATSUKA, HIDENORI;SUGAMA, HIROSHI;AWAI, NOBUMASA;KAWAGUCHI, TAKAYUKI;TAKAHASHI, YOICHI;IIJIMA, TORU;SHEN, JINGKANG;XIA, GUANGXIN;XIE, JIANSHU |